AIM Immunotech vs Azitra
AIM Immunotech and Azitra are similar in size: $88,000 and $0 of revenue in their latest fiscal years. AIM Immunotech grew faster (-48.2% against -100.0%).
| Latest fiscal year | AIM ImmunotechAIM, 2025 | AzitraAZTR, 2025 |
|---|---|---|
| Revenue | $88,000 | $0 |
| Revenue growth | -48.2% | -100.0% |
| Net income | −$14.0m | −$11.0m |
| Operating margin | -13254.5% | — |
| Net margin | -15861.4% | — |
| Return on equity | — | — |
| Free cash flow | −$11.0m | −$11.2m |
| Cash | $3.0m | $2.1m |
| Total debt | $8.0m | $0 |
| Debt to equity | — | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 19 | 13 |
| Market value | $4.7m | $53.9m |
| Price vs our value range | — | — |
| Moat score | 5 (Weak) | — |
| Insider trades, 12 months | 6 buys, 0 sales | 0 buys, 0 sales |